• SELECT SITE CURRENCY
Select a currency for use throughout the site
DRG Insights: Multiple Sclerosis (G7)
Decision Resources, Inc, May 2012, Pages: 54
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Following the 2010 launch of Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera), the market for disease-modifying multiple sclerosis (MS) therapies has begun a dramatic transformation.
A broad array of new and promising anti-inflammatory treatments is rapidly approaching launch, including alternative oral agents with significant potential for early-line use and new parenteral therapies that could redefine efficacy. Novel therapies will drive growth of the MS market through 2017, but the gains will be tempered over the near term by a conservative prescriber base and lingering favoritism for time-tested current agents.
Moreover, in the next ten years, the advent of generics competition for several players will represent a key inflection point in the seemingly price-insensitive specialty MS market. All new agents are expected to be approved to treat relapsing forms of MS; ample opportunity will remain for therapies to treat the underserved population of patients who suffer progressive forms of MS.
Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Key Metrics Population Dynamics
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Unmet Needs Emerging Therapies
Important Endpoints in Prescribing Decisions
Timelines 2010 and 2010 sales and Market Share